Skip to content
Advertisement

FILE - In this March 16, 2020, file photo, Neal Browning receives a shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, at the Kaiser Permanente Washington Health Research Institute in Seattle. The first experimental COVID-19 vaccine in the U.S. is on track to begin a huge study next month to prove if it really can fend off the coronavirus, its manufacturer announced Thursday, June 11 -- a long-awaited step in the global vaccine race. The vaccine, developed by the U.S. National Institutes of Health and Moderna Inc., will be tested in 30,000 volunteers -- some given the real shot and some a dummy shot. (AP Photo/Ted S. Warren, File)

FILE - In this March 16, 2020, file photo, Neal Browning receives a shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, at the Kaiser Permanente Washington Health Research Institute in Seattle. The first experimental COVID-19 vaccine in the U.S. is on track to begin a huge study next month to prove if it really can fend off the coronavirus, its manufacturer announced Thursday, June 11 -- a long-awaited step in the global vaccine race. The vaccine, developed by the U.S. National Institutes of Health and Moderna Inc., will be tested in 30,000 volunteers -- some given the real shot and some a dummy shot. (AP Photo/Ted S. Warren, File)

Featured Photo Galleries